TAC Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy and L-NMMA in Triple Negative Breast Cancer
Condition: Triple Negative Breast Cancer Interventions: Drug: Docetaxel; Drug: Doxorubicin; Drug: Cyclophosphamide; Drug: Pembrolizumab; Drug: IL-12 gene therapy; Drug: L-NMMA Sponsors: The Methodist Hospital System; Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Docetaxel | Gene Therapy | Genetics | Research | Taxotere